Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.
Werewolf Therapeutics Trading Down 0.4 %
NASDAQ HOWL opened at $1.23 on Tuesday. Werewolf Therapeutics has a twelve month low of $1.03 and a twelve month high of $6.89. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The stock has a market cap of $54.59 million, a price-to-earnings ratio of -0.80 and a beta of 0.37. The firm's 50 day moving average price is $1.38 and its two-hundred day moving average price is $1.83.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a report on Tuesday, November 19th. JMP Securities lowered their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating on the stock in a research report on Tuesday, January 14th.
Check Out Our Latest Report on Werewolf Therapeutics
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Werewolf Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.
While Werewolf Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
